BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 1, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» 3Z and Biotx.ai partnership to utilize AI modeling to advance ADHD drug development
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
3Z and Biotx.ai partnership to utilize AI modeling to advance ADHD drug development
Aug. 21, 2023
No Comments
3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD).
BioWorld Science
Artificial intelligence
Drug design, drug delivery and technologies
Collaboration
Neurology/psychiatric
